AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades'

On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. GILD is an inexpensive way to give biotech exposure.

Gilead Sciences, last month, said that it has purchased 15 million shares of HOOKIPA Pharma Inc HOOK for approximately $21.25 million, at $1.4167 per share.

Jim Lebenthal of Cerity Partners said AbbVie Inc. ABBV is a "good one" in the healthcare space.

AbbVie remained confident in Botox’s resilience in the aesthetics market, assured by its ability to sustain a dominant 68% share, as highlighted by Chief Commercial Officer Jeffrey Stewart during the J.P. Morgan healthcare conference.

Don’t forget to check out our premarket coverage here

Jenny Harrington of Gilman Hill Asset Management said Verizon Communications Inc. VZ has 7% yield and eight times earnings.

Verizon Communications disclosed a substantial $5.8 billion write-down in the value of its business services division, reflecting challenges in its enterprise operations.

Joseph Terranova of Virtus Investment Partners picked Arch Capital Group Ltd. ACGL, saying, "Buy the bounce."

Last week, UBS analyst Brian Meredith maintained Arch Capital Group with a Buy and lowered the price target from $101 to $97.

Price Action: Gilead Sciences shares gained 0.6% to close at $86.48; AbbVie gained 0.4% to close at $162.04 on Wednesday; Verizon fell 1.1% to $38.87; Arch Capital gained by 0.6% to $78.67 during Wednesday’s session.

Check This Out: Top 3 Defensive Stocks That May Fall Off A Cliff This Quarter

Image: Shutterstock